Pub Date : 2024-04-17DOI: 10.15829/1560-4071-2024-5831
A. Kochergina, V. Kashtalap
The effectiveness of blood pressure control can be increased with the use of single-pill combinations. When choosing an agent, the evidence of its components should be focused. The selection criteria are not only the direct effects of reducing blood pressure, but also organ protection and the impact on prognosis. Perindopril and indapamide have many years of experience in use in a wide range of patients and are used with the same effectiveness in the treatment of hypertension in young and elderly patients, in normal-weight and obese people, as tools for the primary prevention of myocardial infarction and stroke, and also as a way to prevent recurrent events.The article provides data on the advantages of perindopril and indapamide, the potential of its single-pill combination, the pleiotropic and organ protective properties of this drug. We systematized results of related studies and reflected the main conclusions. Attention is paid to the latest data on the long-term effect of indapamide therapy on the risk of cardiovascular events.
{"title":"Single-pill combination of indapamide and perindopril: potential of practical application","authors":"A. Kochergina, V. Kashtalap","doi":"10.15829/1560-4071-2024-5831","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5831","url":null,"abstract":"The effectiveness of blood pressure control can be increased with the use of single-pill combinations. When choosing an agent, the evidence of its components should be focused. The selection criteria are not only the direct effects of reducing blood pressure, but also organ protection and the impact on prognosis. Perindopril and indapamide have many years of experience in use in a wide range of patients and are used with the same effectiveness in the treatment of hypertension in young and elderly patients, in normal-weight and obese people, as tools for the primary prevention of myocardial infarction and stroke, and also as a way to prevent recurrent events.The article provides data on the advantages of perindopril and indapamide, the potential of its single-pill combination, the pleiotropic and organ protective properties of this drug. We systematized results of related studies and reflected the main conclusions. Attention is paid to the latest data on the long-term effect of indapamide therapy on the risk of cardiovascular events.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140692157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-17DOI: 10.15829/1560-4071-2024-5829
A. Skotnikov, M. Melnik, E. A. Zinina, I. V. Sivertseva
The article is devoted to a detailed analysis of the action of various drugs used in the treatment of hypertension and atherogenic dyslipidemia, depending on their ability to dissolve in fatty media (lipophilicity). The authors analyze connection between the lipophilicity level of drugs and their pharmacokinetics, drug-drug interactions, the manifestations of clinical effects and organ protection, as well as their ability to influence the prognosis of comorbid patients. Using angiotensin-converting enzyme inhibitors, calcium channel blockers, and statins as examples, the authors explain the practical significance of pharmacological parameters such as plasma protein binding and distribution volume, and also develop an understanding of the importance of its routine use in order to obtain clinical benefits for patients.
{"title":"Contribution of lipophilicity to the clinical effects of drugs","authors":"A. Skotnikov, M. Melnik, E. A. Zinina, I. V. Sivertseva","doi":"10.15829/1560-4071-2024-5829","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5829","url":null,"abstract":"The article is devoted to a detailed analysis of the action of various drugs used in the treatment of hypertension and atherogenic dyslipidemia, depending on their ability to dissolve in fatty media (lipophilicity). The authors analyze connection between the lipophilicity level of drugs and their pharmacokinetics, drug-drug interactions, the manifestations of clinical effects and organ protection, as well as their ability to influence the prognosis of comorbid patients. Using angiotensin-converting enzyme inhibitors, calcium channel blockers, and statins as examples, the authors explain the practical significance of pharmacological parameters such as plasma protein binding and distribution volume, and also develop an understanding of the importance of its routine use in order to obtain clinical benefits for patients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":" 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140690701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-17DOI: 10.15829/1560-4071-2024-5812
E. A. Medvedeva, E. Usova, A. E. Solovyova, M. Dubinina, S. Villevalde, N. Zvartau, E. V. Shlyakhto
The combination of hypertension and chronic kidney disease is a stage of the cardiovascular-renal-metabolic continuum and associated with adverse cardiovascular and renal outcomes. Epidemiological aspects, accessible screening algorithm within outpatient monitoring, availability of modern cardiac and renal protective strategies make it possible to select this high-risk group as a priority for the implementation of effective targeted primary prevention and maintaining the trend of reducing cardiovascular morbidity and mortality in the medium- and long-term.
{"title":"Patients with hypertension and chronic kidney disease as a priority group for primary prevention programs","authors":"E. A. Medvedeva, E. Usova, A. E. Solovyova, M. Dubinina, S. Villevalde, N. Zvartau, E. V. Shlyakhto","doi":"10.15829/1560-4071-2024-5812","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5812","url":null,"abstract":"The combination of hypertension and chronic kidney disease is a stage of the cardiovascular-renal-metabolic continuum and associated with adverse cardiovascular and renal outcomes. Epidemiological aspects, accessible screening algorithm within outpatient monitoring, availability of modern cardiac and renal protective strategies make it possible to select this high-risk group as a priority for the implementation of effective targeted primary prevention and maintaining the trend of reducing cardiovascular morbidity and mortality in the medium- and long-term.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":" 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140691650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-17DOI: 10.15829/1560-4071-2024-5695
M. A. Kokozheva, B. U. Mardanov, M. N. Mamedov
Aim. To study the features of treatment of patients with various types of coronary artery disease (CAD) and type 2 diabetes (T2D) at various healthcare stages.Material and methods. The comparative clinical study included 412 patients of both sexes with acute and chronic coronary artery disease. Depending on the glycemic status and CAD type, patients were divided into four subgroups: subgroup 1a (n=100, 56,6±0,96 years, male/female 67/33) — with acute CAD and T2D; subgroup 1b (n=106, 58,7±1,01 years, male/female 75/31) — with acute CAD without T2D; subgroup 2a (n=102, 57,9±1,04 years, male/female 72/30) — with chronic CAD and T2D; subgroup 2b (n=104, 60,2±0,9 years, 69/35) — with chronic CAD without T2D. The selection and mean doses of standard and hypoglycemic therapy were analyzed.Results. Initially, 86% and 81% of patients with diabetes in subgroups 1a and 2a adhered to glucose-lowering therapy. Among patients with chronic CAD, more than 1/4 (26,4%) received insulin therapy versus 2% in the group of patients with acute coronary syndrome (ACS) and diabetes. After discharge from hospital, oral hypoglycemic therapy was prescribed to 74% of patients with ACS and 48% of patients with chronic CAD. The prescription of insulin therapy for people with ACS increased 5 times (up to 10% of the total number of patients with ACS and T2D). By the time of hospital admission, 70% and 71,5% of patients with ACS and chronic CAD with diabetes received acetylsalicylic acid as an antiplatelet agent, respectively. During hospitalization, all patients with acute CAD were prescribed dual antiplatelet therapy, as well as triple antiplatelet therapy in the case of atrial fibrillation/flutter. It is noteworthy that in the group of patients with chronic CAD, less than 70% received statins. In patients with chronic CAD and diabetes, this parameter was even lower, amounting to 59,8%. At the outpatient stage, all patients, with the exception of the group with chronic CAD without diabetes, took beta-blockers (up to 65%). In the hospital, the use of beta blockers increased to 95%. During inpatient treatment, angiotensin-converting enzyme inhibitors and sartans were prescribed 1,5-2 times more often than in the prehospital stage.Conclusion. The study indicates insufficient prescription of standard CAD and glucose-lowering therapy. Careful inpatient selection of therapy requires continuity at the outpatient stage.
{"title":"Comparative analysis of pharmacotherapy for patients with coronary artery disease and type 2 diabetes at various healthcare stages","authors":"M. A. Kokozheva, B. U. Mardanov, M. N. Mamedov","doi":"10.15829/1560-4071-2024-5695","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5695","url":null,"abstract":"Aim. To study the features of treatment of patients with various types of coronary artery disease (CAD) and type 2 diabetes (T2D) at various healthcare stages.Material and methods. The comparative clinical study included 412 patients of both sexes with acute and chronic coronary artery disease. Depending on the glycemic status and CAD type, patients were divided into four subgroups: subgroup 1a (n=100, 56,6±0,96 years, male/female 67/33) — with acute CAD and T2D; subgroup 1b (n=106, 58,7±1,01 years, male/female 75/31) — with acute CAD without T2D; subgroup 2a (n=102, 57,9±1,04 years, male/female 72/30) — with chronic CAD and T2D; subgroup 2b (n=104, 60,2±0,9 years, 69/35) — with chronic CAD without T2D. The selection and mean doses of standard and hypoglycemic therapy were analyzed.Results. Initially, 86% and 81% of patients with diabetes in subgroups 1a and 2a adhered to glucose-lowering therapy. Among patients with chronic CAD, more than 1/4 (26,4%) received insulin therapy versus 2% in the group of patients with acute coronary syndrome (ACS) and diabetes. After discharge from hospital, oral hypoglycemic therapy was prescribed to 74% of patients with ACS and 48% of patients with chronic CAD. The prescription of insulin therapy for people with ACS increased 5 times (up to 10% of the total number of patients with ACS and T2D). By the time of hospital admission, 70% and 71,5% of patients with ACS and chronic CAD with diabetes received acetylsalicylic acid as an antiplatelet agent, respectively. During hospitalization, all patients with acute CAD were prescribed dual antiplatelet therapy, as well as triple antiplatelet therapy in the case of atrial fibrillation/flutter. It is noteworthy that in the group of patients with chronic CAD, less than 70% received statins. In patients with chronic CAD and diabetes, this parameter was even lower, amounting to 59,8%. At the outpatient stage, all patients, with the exception of the group with chronic CAD without diabetes, took beta-blockers (up to 65%). In the hospital, the use of beta blockers increased to 95%. During inpatient treatment, angiotensin-converting enzyme inhibitors and sartans were prescribed 1,5-2 times more often than in the prehospital stage.Conclusion. The study indicates insufficient prescription of standard CAD and glucose-lowering therapy. Careful inpatient selection of therapy requires continuity at the outpatient stage.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":" 43","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140691143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-14DOI: 10.15829/1560-4071-2024-5766
A. Amineva, I. Lakman, E. Badykova, R. F. Rakhimova, S. S. Dozhdev, D. V. Popov, Z. Khismatullina, N. Zagidullin
Aim. To study serum biomarker profile in patients with coronary artery disease (CAD) and psoriasis and the impact on the incidence of hospitalization for cardiovascular reasons and psoriasis.Material and methods. The study included 90 patients divided into following 3 groups: with psoriasis (n=30), coronary artery disease (CAD) (n=30) and CAD+psoriasis (n=30) in whom serum biomarkers were determined at the beginning of the study (growth stimulation expressed gene 2, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-17 and tumor necrosis factor alpha) and hospitalization rates were monitored over 4 years.Results. There was a significant difference in the concentrations of all biomarkers between the groups (p<0,05), with the maximum values being in the CAD+psoriasis group, except for NT-proBNP. In regression analysis, risk factors for cardiovascular hospitalizations were psoriasis (p=0,049) and increased NT-proBNP concentrations (p<0,001).Conclusion. Comorbidity leads to an increase in the serum concentration of biomarkers, while the risk factors for cardiovascular hospitalization were psoriasis and serum NT-proBNP level.
{"title":"Serum biomarkers in patients with psoriasis and coronary artery disease and their impact on hospitalization: data form a prospective, 4-year, single-center, uncontrolled study","authors":"A. Amineva, I. Lakman, E. Badykova, R. F. Rakhimova, S. S. Dozhdev, D. V. Popov, Z. Khismatullina, N. Zagidullin","doi":"10.15829/1560-4071-2024-5766","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5766","url":null,"abstract":"Aim. To study serum biomarker profile in patients with coronary artery disease (CAD) and psoriasis and the impact on the incidence of hospitalization for cardiovascular reasons and psoriasis.Material and methods. The study included 90 patients divided into following 3 groups: with psoriasis (n=30), coronary artery disease (CAD) (n=30) and CAD+psoriasis (n=30) in whom serum biomarkers were determined at the beginning of the study (growth stimulation expressed gene 2, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-17 and tumor necrosis factor alpha) and hospitalization rates were monitored over 4 years.Results. There was a significant difference in the concentrations of all biomarkers between the groups (p<0,05), with the maximum values being in the CAD+psoriasis group, except for NT-proBNP. In regression analysis, risk factors for cardiovascular hospitalizations were psoriasis (p=0,049) and increased NT-proBNP concentrations (p<0,001).Conclusion. Comorbidity leads to an increase in the serum concentration of biomarkers, while the risk factors for cardiovascular hospitalization were psoriasis and serum NT-proBNP level.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140704817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-04DOI: 10.15829/1560-4071-2024-5887
M. I. Shperling, S. P. Salikova
.
.
{"title":"In memory of Andrei A. Vlasov","authors":"M. I. Shperling, S. P. Salikova","doi":"10.15829/1560-4071-2024-5887","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5887","url":null,"abstract":"<jats:p>.</jats:p>","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140742522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-24DOI: 10.15829/1560-4071-2024-5806
T. Chernyavskaya, S. N. Erofeeva
Aim. To assess vascular age (VA) and the main cardiovascular risk factors (chronological age, body mass index (BMI), carotid-femoral pulse wave velocity (PWV), blood pressure (BP)) in women in the Moscow region.Material and methods. We assessed BP levels, BMI, PWV, and also calculate vascular age for women participating in the forum. BMI was calculated using the Quetelet index as weight divided by height squared (BMI=kg/m2). BP levels were measured in a sitting position three times on both arms, with the highest result recorded. PWV and vascular age were calculated using AngioScan01. The association between anthropometric measures, vascular stiffness, and VA differences was examined using multivariate linear regression, adjusting for traditional cardiovascular risk factors. Intergroup (systolic blood pressure <140 mm Hg and ≥140 mm Hg) comparisons of PWV and VA difference from actual were performed using a modified Welch's t-test.Results. The study involved 260 women. The mean age was 44,92±0,85 years (95% confidence interval (CI) 43,27-46,57), mean vascular age — 45,90±1,01 (95% CI 43,91-47,89), mean BMI — 23,383±0,66 kg/m2 (95% CI 22,046-24,720). Mean systolic BP was 127,63±1,89 mm Hg (95% CI 123,89-131,36), diastolic BP 80,031±0,93 (95% CI 78,20-81,86), mean PWV was 11,38±0,16 m/sec (95% CI 11,05-11,70). Analysis of the VA difference between women with BMI <25 kg/m2 (BMI1, n=93) and ≥25 kg/m2 (BMI2, n=67) revealed a significant difference in the calculated VA values (p=0,0002) between groups.Conclusion. Modern young women have high rates of vascular stiffness, which may determine the increase in morbidity and mortality rates in the working-age female population. The VA indicator predicts cardiovascular events and can be considered as an effective screening method for assessing cardiovascular risk, which is especially important for young patients.
目的评估莫斯科地区妇女的血管年龄（VA）和主要心血管风险因素（实际年龄、体重指数（BMI）、颈动脉-股动脉脉搏波速度（PWV）、血压（BP））。我们对参加论坛的妇女的血压水平、体重指数、脉搏波速度进行了评估，并计算了血管年龄。体重指数采用 Quetelet 指数计算，即体重除以身高的平方（BMI=kg/m2）。在坐姿下测量双臂血压三次，记录最高结果。脉搏波速度和血管年龄使用 AngioScan01 进行计算。在对传统心血管风险因素进行调整后，采用多变量线性回归法对人体测量指标、血管僵硬度和 VA 差异之间的关系进行了研究。组间（收缩压<140毫米汞柱和≥140毫米汞柱）脉搏波速度和VA与实际差异的比较采用改良韦尔奇t检验法进行。研究涉及 260 名女性。平均年龄为（44.92±0.85）岁（95% 置信区间（CI）为 43.27-46.57），平均血管年龄为（45.90±1.01）岁（95% 置信区间（CI）为 43.91-47.89），平均体重指数为（23.383±0.66）千克/平方米（95% 置信区间（CI）为 22.046-24.720）。平均收缩压为 127,63±1,89 毫米汞柱（95% CI 123,89-131,36），舒张压为 80,031±0,93 （95% CI 78,20-81,86），平均脉搏波速度为 11,38±0,16 米/秒（95% CI 11,05-11,70）。对体重指数＜25 千克/平方米（BMI1，n=93）和≥25 千克/平方米（BMI2，n=67）的女性之间的脉搏波速度差异进行分析后发现，各组之间的脉搏波速度计算值存在显著差异（P=0,0002）。现代年轻女性的血管僵化率很高，这可能决定了工作年龄女性发病率和死亡率的上升。VA指标可预测心血管事件，可被视为评估心血管风险的有效筛查方法，这对年轻患者尤为重要。
{"title":"Assessment of vascular age and cardiovascular risk factors among young women in the Moscow region","authors":"T. Chernyavskaya, S. N. Erofeeva","doi":"10.15829/1560-4071-2024-5806","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5806","url":null,"abstract":"Aim. To assess vascular age (VA) and the main cardiovascular risk factors (chronological age, body mass index (BMI), carotid-femoral pulse wave velocity (PWV), blood pressure (BP)) in women in the Moscow region.Material and methods. We assessed BP levels, BMI, PWV, and also calculate vascular age for women participating in the forum. BMI was calculated using the Quetelet index as weight divided by height squared (BMI=kg/m2). BP levels were measured in a sitting position three times on both arms, with the highest result recorded. PWV and vascular age were calculated using AngioScan01. The association between anthropometric measures, vascular stiffness, and VA differences was examined using multivariate linear regression, adjusting for traditional cardiovascular risk factors. Intergroup (systolic blood pressure <140 mm Hg and ≥140 mm Hg) comparisons of PWV and VA difference from actual were performed using a modified Welch's t-test.Results. The study involved 260 women. The mean age was 44,92±0,85 years (95% confidence interval (CI) 43,27-46,57), mean vascular age — 45,90±1,01 (95% CI 43,91-47,89), mean BMI — 23,383±0,66 kg/m2 (95% CI 22,046-24,720). Mean systolic BP was 127,63±1,89 mm Hg (95% CI 123,89-131,36), diastolic BP 80,031±0,93 (95% CI 78,20-81,86), mean PWV was 11,38±0,16 m/sec (95% CI 11,05-11,70). Analysis of the VA difference between women with BMI <25 kg/m2 (BMI1, n=93) and ≥25 kg/m2 (BMI2, n=67) revealed a significant difference in the calculated VA values (p=0,0002) between groups.Conclusion. Modern young women have high rates of vascular stiffness, which may determine the increase in morbidity and mortality rates in the working-age female population. The VA indicator predicts cardiovascular events and can be considered as an effective screening method for assessing cardiovascular risk, which is especially important for young patients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"41 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140434302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-15DOI: 10.15829/1560-4071-2024-5689
S. L. Grishaev, D. V. Cherkashin, V. Salukhov, A. E. Alanichev
The review summarizes and analyzes the available literature to provide information to clinicians about the best treatment strategies for type 2 diabetes in stable coronary artery disease. This data should help health care professionals make decisions in routine practice. 2023 European and Russian guidelines on type 2 diabetes suggest giving preference to glucose-lowering agents with proven benefits for the cardiovascular system, followed by drugs with proven safety for the cardiovascular system.
{"title":"Modern strategies for the treatment of type 2 diabetes in patients with stable coronary artery disease. Old goals, new opportunities (literature review)","authors":"S. L. Grishaev, D. V. Cherkashin, V. Salukhov, A. E. Alanichev","doi":"10.15829/1560-4071-2024-5689","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5689","url":null,"abstract":"The review summarizes and analyzes the available literature to provide information to clinicians about the best treatment strategies for type 2 diabetes in stable coronary artery disease. This data should help health care professionals make decisions in routine practice. 2023 European and Russian guidelines on type 2 diabetes suggest giving preference to glucose-lowering agents with proven benefits for the cardiovascular system, followed by drugs with proven safety for the cardiovascular system.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"20 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140507361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-10DOI: 10.15829/1560-4071-2024-5747
M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov
Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.
{"title":"First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation","authors":"M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov","doi":"10.15829/1560-4071-2024-5747","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5747","url":null,"abstract":"Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"52 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140511109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-09DOI: 10.15829/1560-4071-2024-5604
I. A. Bulavina, Yu. D. Vaisman, A. M. Baimukanov, M. V. Yunyaeva, I. L. Ilyich, S. A. Termosesov
In recent decades, there has been increased interest in obstructive sleep apnea (OSA), especially in patients with a combination of OSA and sleep bradyarrhythmias. Worldwide, the diagnosis of OSA is steadily increasing. Increasingly, clinicians have begun to use CPAP therapy to treat sleep-related bradyarrhythmias. But in world practice there are no unambiguous guidelines for the management of this group of patients.
近几十年来，人们越来越关注阻塞性睡眠呼吸暂停（OSA），尤其是合并有 OSA 和睡眠缓慢性心律失常的患者。在全球范围内，OSA 的诊断率正在稳步上升。越来越多的临床医生开始使用 CPAP 治疗来治疗与睡眠相关的缓慢性心律失常。但在世界范围内，对这类患者的管理还没有明确的指导方针。
{"title":"Obstructive sleep apnea in bradyarrhythmias","authors":"I. A. Bulavina, Yu. D. Vaisman, A. M. Baimukanov, M. V. Yunyaeva, I. L. Ilyich, S. A. Termosesov","doi":"10.15829/1560-4071-2024-5604","DOIUrl":"https://doi.org/10.15829/1560-4071-2024-5604","url":null,"abstract":"In recent decades, there has been increased interest in obstructive sleep apnea (OSA), especially in patients with a combination of OSA and sleep bradyarrhythmias. Worldwide, the diagnosis of OSA is steadily increasing. Increasingly, clinicians have begun to use CPAP therapy to treat sleep-related bradyarrhythmias. But in world practice there are no unambiguous guidelines for the management of this group of patients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"129 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140511702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：